ArticleACS omega2025
A Natural Extract Derived from Fish Scales Prevents Type 1 Diabetes in Nonobese Diabetic Mice by Modulating Gut Microbiota and Serum Metabolomics.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of pancreatic β-cells and persistent hyperglycemia. The rising global incidence of T1D highlights the need for novel preventive and therapeutic strategies. Fish scale gel (FSG), a marine-derived natural extract rich in collagen peptides, lecithin, unsaturated fatty acids, and chitin, has demonstrated anti-inflammatory and wound-healing properties. However, its potential in modulating the gut microbiota, host metabolism, and pancreatic inflammation during early T1D remains unclear. In this study, nonobese diabetic (NOD) mice were orally administered low, medium, or high doses of FSG for 24 weeks. FSG was well tolerated and significantly reduced random blood glucose levels, improved glucose tolerance, and mitigated body weight loss. Histological and immunohistochemical analyses revealed alleviated islet inflammation and reduced infiltration of immune cells, accompanied by lower expression of interleukin-6 (IL-6) and interferon-γ (IFN-γ). Gut microbiota profiling showed that FSG reversed diabetes-associated dysbiosis by increasing beneficial genera (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.